TY - JOUR
T1 - BCG Vaccine and Its Derivatives
T2 - Potential, Practical Considerations, and Precautions in Human Cancer Immunotherapy
AU - Hersh, Evan M.
AU - Gutterman, Jordan U.
AU - Mavligit, Giora M.
AU - Reed, Richard C.
AU - Richman, Stephen P.
PY - 1976/2/9
Y1 - 1976/2/9
N2 - BCG vaccine is undergoing extensive clinical trials for cancer immunotherapy. These studies are based on its immunopotentiating and macrophage-activating properties. Efficacy of BCG vaccine probably depends on strain, proportion of viable organisms, absence of free soluble antigens, dose, route, and schedule of administration. BCG vaccine is most efficacious when administered in conjunction with or following intensive cytoreductive maneuvers such as surgery, radiotherapy, or chemotherapy. BCG vaccine has shown beneficial activity in acute myelogenous leukemia, malignant melanoma, colon cancer, lymphoma, head and neck cancer, and other tumors. Since BCG vaccine has toxic side effects, and since less than optimal preparations can be detrimental in terms of tumor control, progress in the development of BCG vaccine immunotherapy must be based on sound clinical trials, careful clinical and immunological evaluation of treated subjects, and continuing research on basic and applied aspects of its immunological and other biological activities.
AB - BCG vaccine is undergoing extensive clinical trials for cancer immunotherapy. These studies are based on its immunopotentiating and macrophage-activating properties. Efficacy of BCG vaccine probably depends on strain, proportion of viable organisms, absence of free soluble antigens, dose, route, and schedule of administration. BCG vaccine is most efficacious when administered in conjunction with or following intensive cytoreductive maneuvers such as surgery, radiotherapy, or chemotherapy. BCG vaccine has shown beneficial activity in acute myelogenous leukemia, malignant melanoma, colon cancer, lymphoma, head and neck cancer, and other tumors. Since BCG vaccine has toxic side effects, and since less than optimal preparations can be detrimental in terms of tumor control, progress in the development of BCG vaccine immunotherapy must be based on sound clinical trials, careful clinical and immunological evaluation of treated subjects, and continuing research on basic and applied aspects of its immunological and other biological activities.
UR - http://www.scopus.com/inward/record.url?scp=0017228126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017228126&partnerID=8YFLogxK
U2 - 10.1001/jama.1976.03260320052031
DO - 10.1001/jama.1976.03260320052031
M3 - Article
AN - SCOPUS:0017228126
VL - 235
SP - 646
EP - 650
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
SN - 0002-9955
IS - 6
ER -